BridgeBio Oncology Therapeutics (BBOT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.54
- Surprise
- —
- Score today
- 5.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates BBOT Sell at 5.0/10; no pre/post engine snapshot brackets this report.
1 of the last 3 quarters beat the estimate. Next scheduled report: 2026-11-11.
What argues against it
- Quality below floor (1.9 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -30.9%), Material insider selling (26 sells, 3.00% of cap)
- Momentum score 3.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.21
- Price target
- $21.66
- Stop
- $8.44
- Upside to target
- +135.2%
- Reward-to-risk
- 11.7:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
BBOT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $728.0M
- P/E (fwd)
- -3.8
- 52-week range
- $7.00–$14.87
- Off 52-week high
- 38.1%
- RSI (14)
- 62
- Volume vs avg
- 0.65×
- Score today
- 5.0/10